Medincell Stock Rises Nearly 3% and Leads the Pack in the SBF 120
The biotech company from Montpellier advances in mid-morning trading, bucking the trend of a Parisian market weighed down by inflationary fears linked to the oil shock. The stock confirms its medium-term momentum.
A 2.61% Increase Elevates the Stock Among the Top Gainers of the SBF 120
Medincell gains 2.61% to €27.54 in mid-morning trading, while the SBF 120 drops by 0.67% and the CAC 40 declines by 0.70%. The movement extends the upward trend documented last week, following a 2% increase observed on Friday. Over three months, the performance is close to 29%, and reaches nearly 71% over one year, showing a trajectory significantly disconnected from the broader index. Today's rise places the share price above the MM20 (€27.17, a gap of +1.4%), while the stock maintains a comfortable cushion relative to its longer averages, about 9.6% above the MM50 and 8.1% above the MM200.
Short Position Accumulated to 2.55% of Capital, Up by 1.09 Points Over a Month
Four funds now cumulatively hold 2.55% of the capital in short positions, according to reviewed declarations, up from 1.46% thirty days ago. The increase reaches 1.09 points in a month, a notable rise even though the cumulative total remains modest relative to the float. This implies that some institutional investors are reinforcing a position contrary to the stock's bullish movement, either betting on a consolidation after the rally or to hedge an existing exposure. The figure is worth monitoring but should not be overinterpreted: it remains far from the stress levels observed on other SBF 120 stocks. Technically, the RSI at 53 remains neutral and does not send an extreme signal. The resistance of €28.72, already tested at the end of May and then on June 2 according to recent briefs, becomes the immediate graphical reference, less than 5% from the current price.
